Section Arrow
Quote
ELTX.NASDAQ
- Elicio Therapeutics, Inc.
Quotes are at least 15-min delayed:2026/06/09 16:25 EDT
After Hours
Last
 14.2
-- (--)
Bid
14
Ask
14.1
High 14.2 
Low 14.2 
Volume 159 
Regular Hours (Closed)
Last
 14.2
+0.65 (+4.80%)
Day High 
14.2 
Prev. Close
13.55 
1-M High
14.97 
Volume 
127.07K 
Bid
14
Ask
14.1
Day Low
12.76 
Open
13.61 
1-M Low
9.115 
Market Cap 
258.62M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.97 
20-SMA 11.16 
50-SMA 11.06 
52-W High 14.97 
52-W Low 7.37 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.36/-1.87
Enterprise Value
272.12M
Balance Sheet
Book Value Per Share
-0.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.028-0.0219-43.89%-- 
After Hours 0.0268 -- --
NUVLNuvalent123.22+34.73+39.25%-- 
After Hours 123.33 -- --
RXRXRecursion Pharmaceuticals3.22-0.1-3.01%-- 
After Hours 3.23 -- --
GERNGeron Corp1.115-0.015-1.33%-- 
After Hours 1.1293 -- --
GOSSGossamer Bio0.1554-0.0102-6.16%-- 
After Hours 0.1574 -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.